Hyperfine (HYPR) Long-Term Investments (2021)
Hyperfine's (HYPR) quarterly Long-Term Investments came in at $207.0 million in Q3 2021, little changed on a QoQ basis from $207.0 million in Q2 2021.
Hyperfine (HYPR) Long-Term Investments (2021) Analysis & Trends
Hyperfine (HYPR) has 1 years of Long-Term Investments data on file, last reported at $207.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 1.11 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | - |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 2.25 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 244.10 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 175.52 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | - |
| 10 | Hyperfine | 89.83 Mn | 45.06 Mn | 1.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 207.01 Mn |
| Jun 30, 2021 | 207.01 Mn |
| Mar 31, 2021 | 207.00 Mn |